Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid
Planegg/Martinsried, April 8, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior.
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced
Planegg/Martinsried, April 4, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the.
Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program.